LSTA

#4421
Lisata Therapeutics, Inc. Common Stock
4.56 USD
+0.66%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
4.50
4.65
Intervallo Annuale
1.81
5.06
Variazione giornaliera
+0.66%
Variazione Mensile
-9.52%
Variazione di 6 mesi
+91.60%
Variazione Annuale
+103.57%
Chiusura Precedente
4.53
Apertura
4.50
Bid
Ask
Minimo
4.50
High
4.65
Volume
5
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Lisata Therapeutics Inc

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Notizie